Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax (NVAX) closed the most recent trading day at $7.64, moving -2.55% from the previous trading session. This move lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow experienced a drop ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Novavax Inc. closed 61.37% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

Novavax has reached a settlement with Gavi, the Vaccine Alliance (Gavi), ending arbitration tied to a 2021 advance purchase agreement (APA) around its prototype COVID-19 vaccine NVX-CoV2373.

Novavax and S&P 500 Performance During 2007-08 Crisis NVAX stock declined from $73 in September 2007, the pre-crisis peak, to $16 in March 2009, as the markets bottomed out, implying it lost 78% ...

Novavax’s recent application for licensing its Covid-19 vaccine in Australia, Canada, and the UK hasn’t gained much traction in the US media. This is odd, given that the vaccine could not only ...